Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Sernova — Investor Presentation (May 2023)
21 slides from Sernova Biotherapeutics's investor presentation, May 2023

Slide 1: Advancing cell therapeutics to provide 'functional cures'
Advancing cell therapeutics to provide ‘functional cures’ Q2 2023 Corporate Presentation

Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expects

Slide 3: Capital Structure / Select Information
Capital Structure / Select Information EXCHANGE: 52-week Range 1 $0.69 - 2.22 TSX: SVA Shares Outstanding 303 million OTCQB: SEOVF Market Cap 1 $300 million FSE / XETRA: PSH Average Daily Volume 2 0.23 million Cash (1/31/23) $45.6 million FISCAL Y/E: 10/31 Debt $0 Analyst Coverage 1All figures as of

Slide 4: Sernova: Innovator and Leader
Sernova: Innovator and Leader Cell Therapeutics: Paradigm Shift for Superior Treatment of High-Maintenance, Lifelong Conditions • Sernova’s integrated Cell Pouch System™ provides the potential for a ‘functional cure’ for chronic medical conditions with multi-billion dollar market potential • Cell Po

Slide 5: Sernova's Integrated Cell Therapeutics Solution
Sernova’s Integrated Cell Therapeutics Solution • 1st generation utilizes human donor cells • Proprietary implantable medical device • 2nd generation off-the-shelf stem cell derived cells • Provides vascularized environment for therapeutic cells to survive for long periods • i.e. Evotec iPSC islet o

Slide 6: Pipeline – Life Cycle Iterations and Multiple Indications
Pipeline – Life Cycle Iterations and Multiple Indications Lead Program Has Demonstrated POC Efficacy & Excellent Safety in Type 1 Diabetes Product Therapeutic Candidate Indication Cell Source Immune Protection Discovery Pre-Clinical Phase 1/2 Phase 3 BLA Human donor Immunosuppressives islet cells Ce

Slide 7: Diabetes Global Disease = Global Market
DIABETES GLOBAL DISEASE = GLOBAL MARKET Diabetes is one of the most prevalent diseases and most pervasive medical problems impacting society and quality of life today. 537 million people are affected worldwide with diabetes; another estimated 179 million people have it without knowing it. By 2045, p

Slide 8: The Advantages of Pancreatic Islets
The Advantages Of Pancreatic Islets Over ed ° Alpha Cells Beta Cells Insulin : : Injection Pancreatic Islets: The Complete Approach lets global regula\ Sernova’s Cell Pouch System™ Evotec is manufactur tic islet-ike clusters (ILCs) that mimic the funct n islets. Sernovas Cell Pouch, in combination w

Slide 9: Phase 1/2 T1D Study Design – First Cohort
Phase 1/2 T1D Study Design – First Cohort Patients with Type 1 Diabetes and Hypoglycemia Unawareness Trial Overview • Open label, single-arm, single-center trial (n=7) • Insulin-dependent T1D patients with hypoglycemia unawareness Study • Cell Pouch implant followed by two sequential human donor isl

Slide 10: Phase 1/2 T1D Study Interim Results – First Cohort
Phase 1/2 T1D Study Interim Results – First Cohort ADA Presentation June 2022 • Surgical implantation of the Cell Pouch was found to be well tolerated with a favorable safety profile • All patients who had favorable immunosuppression achieved complete insulin independence • First three transplanted

Slide 11: Phase 1/2 Study – Cohort 1 Informed / Guided to Cohort 2
Phase 1/2 Study – Cohort 1 Informed / Guided to Cohort 2 Advancing With A Higher Capacity Cell Pouch Product • Cohort 1 (6 patients) o Patients demonstrated a clear safety profile for Cell Pouch System o Established threshold for islet dose and density optimization o Cohort 1 update coming at Americ

Slide 12: Abundant Supply of iPSC Insulin Producing Islet Clusters
Abundant Supply of iPSC Insulin Producing Islet Clusters • Secured exclusive option on exclusive global license for Evotec’s ethically derived iPSC insulin producing islet clusters for use with Sernova’s Cell Pouch System or alone with other technologies • Access to unlimited supply of insulin-produ

Slide 13: Sernova & Evotec iPSC Manufacturing Process/ Patient Experience
Sernova & Evotec iPSC Manufacturing Process/ Patient Experience 13

Slide 14: iPSC-derived Islet-Like Clusters with Long-Term Antidiabetic Efficacy
iPSC-derived Islet-Like Clusters (ILCs) with Long-Term Antidiabetic Efficacy Robust, durable normalization of glycemic control in diabetic mice Efficient normalization of random fed glucose Circulating hC-peptide by kidney capsule-implanted ILCs Evotec GMP manufacturing site near Modena/Italy • We h

Slide 15: Combining High Quality iPSC-Derived ILCs with a Clinically Proven Device
Combining High Quality iPSC-Derived ILCs with a Clinically Proven Device Evotec ILCs with Sernova Cell PouchTM • The Sernova Cell PouchTM is a pre- implanted, vascularized device providing an optimal environment for therapeutic cell function1 − Accessible/retrievable implantation site • Sernova has

Slide 16: Excellent Anti-Diabetic Activity of ILCs in the Cell Pouch
Excellent Anti-Diabetic Activity of ILCs in the Cell PouchTM Rapid normalization of glycemic control with human islet-like potency Efficient normalization of random fed glucose Robust circulating hC-peptide levels Efficient glucose mouse glucose setpoint clearance and no hypoglycemias in oGTT (8 wee

Slide 17: Excellent Anti-Diabetic Activity of an ILC/Cell Pouch Combination
Excellent Anti-Diabetic Activity of an ILC/Cell Pouch™ Combination Summary • We have set up a scalable GMP manufacturing workflow from GMP iPS cells to ILCs, yielding a high beta cell fraction drug product − ILCs are cryopreserved at a late intermediate stage − Endocrine differentiation is complete

Slide 18: Conformal Coating Technology – for Immune Protection
Conformal Coating Technology – for Immune Protection • ‘Shrink wrap’ properties • Thin biocompatible cross-linked allows volume of transplanted polymer hydrogel coating that cells into the Cell Pouch to be surrounds therapeutic cells Conformal Coating – unaffected University of Miami / Sernova Colla

Slide 19: Cell Pouch System for Hypothyroidism & Hemophilia A
Cell Pouch System for Hypothyroidism & Hemophilia A Therapeutic Benefits & Estimated Market Hypothyroidism Hemophilia A ➔ ➔ 20,000 patients across North America and EU ➔ 150,000 thyroidectomies performed annually in the US alone $10B orphan indication Estimated ➔ $2.2B market opportunity Market Size

Slide 20: Upcoming Catalysts
Upcoming Catalysts Anticipated Milestones and Data 2023 • Immune protection update H1 2023 • US Phase 1/2 T1D second cohort patient enrollment update H1 2023 • US Phase 1/2 T1D first cohort clinical update Q2 2023 • US Phase 1/2 T1D second cohort clinical update Q4 2023 • FDA interactions regarding

Slide 21: TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH
TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH Business Development Investor Relations Dr. Philip Toleikis Head Office Christopher Barnes VP, Investor Relations 1.519.858.5184 700 Collip Circle, Ste 114 philip.toleikis@sernova.com 1.519.902.7923 London, ON, Canada N6G 4X8 christopher.barnes@sernova.com Tel:
Source: Internet Archive copy of sernova.com
More decks from Sernova Biotherapeutics Inc
Merger or Acquisition (2026)16 slides · 2026
Investor Presentation (February 2025)24 slides · February 2025
Investor Presentation (December 2024)31 slides · December 2024
Investor Presentation (September 2024)21 slides · Sep 12, 2024
Investor Presentation (March 2024)32 slides · March 2024
Sernova — Investor Presentation (September 2023)27 slides · September 2023